Drug Trial Radar · NCT06627088
A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Aug 23, 2024
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \[14C\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \[14C\]-LY4100511, LY4100511, and TRA.
Conditions
- Healthy
Interventions
LY4100511 (DC-853)Drug
Administered oral dose
[14C]-LY4100511 (DC-853) Administered oral doseDrug
Administered oral dose
LY4100511 (DC-853)Drug
Administered oral dose
[14C]-LY4100511 (DC-853)Drug
Administered IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Total Radioactivity Recovery and Excretion (TRA)Time frame: Up until Day 15
- Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for [14C] LY4100511Time frame: Up until Day 15
- Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for LY4100511Time frame: Up until Day 15
- Part A: Pharmacokinetic (PK): Area Under the Concentration from Time 0 to Infinity (AUC0-∞) for TRATime frame: Up until Day 15
- Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for [14C] LY4100511Time frame: Up until Day 15
- Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for LY4100511Time frame: Up until Day 15
- Part A: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) for TRATime frame: Up until Day 15
- Part A: PK Maximum Observed Plasma Concentration (Cmax) for [14C] LY4100511Time frame: Up until Day 15
- Part A: PK Maximum Observed Plasma Concentration (Cmax) for LY4100511Time frame: Up until Day 15
- Part A: PK Maximum Observed Plasma Concentration (Cmax) for TRATime frame: Up until Day 15
- Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for [14C] LY4100511Time frame: Up until Day 15
- Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for LY4100511Time frame: Up until Day 15
- Part A: PK Time to Maximum Observed Plasma Concentration (tmax) for TRATime frame: Up until Day 15
- Part A: PK Terminal Elimination Half Life (t1/2) for [14C] LY4100511Time frame: Up until Day 15
- Part A: PK Terminal Elimination Half Life (t1/2) for LY4100511Time frame: Up until Day 15
- Part A: PK Terminal Elimination Half Life (t1/2) for TRATime frame: Up until Day 15
- Part A: Urinary Recovery and Excretion of TRA (Aet1-t2)Time frame: Up until Day 15
- Part A: Urinary Recovery and Excretion of [14C] LY4100511 (Aet1-t2)Time frame: Up until Day 15
- Part A: Renal clearance of [14C] LY4100511 (CLR)Time frame: Up until Day 15
- Part B: Pharmacokinetic (PK): absolute bioavailability (Fabs) of LY4100511Time frame: Up until Day 6
- Part B: Recovery of TRA in urine and fecesTime frame: Up until Day 6
- Part B: Recovery of [14C]-LY4100511 in feces (Aet1-t2) following IV dosingTime frame: Up until Day 6
- Part B: Recovery of [14C]-LY4100511 in urine (Aet1-t2) following IV dosingTime frame: Up until Day 6
- Part B: PK Area Under Concentration from 0 to Last Measurable Concentration (AUC0-tlast) of LY4100511 following IV dosingTime frame: Up until Day 6
- Part B: PK Maximum Observed Plasma Concentration (Cmax) of LY4100511following IV dosingTime frame: Up until Day 6
- Part B: PK Time to Maximum Observed Plasma Concentration (tmax) of LY4100511following IV dosingTime frame: Up until Day 6
- Part B: PK Terminal Elimination Half Life (t1/2) following IV dosingTime frame: Up until Day 6
- Part B: PK Clearance (CL) following IV dosingTime frame: Up until Day 6
- Part B: PK renal clearance (CLr) following IV dosing [Time Frame: Up until Day 6]Time frame: Up until Day 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fortrea Clinical Research Unit
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.